Why TransMedics (TMDX) is a Top Momentum Stock for the Long-Term

TransMedics (TMDX), a medical technology company, is identified as a top momentum stock despite holding a Zacks Rank of #3 (Hold). The company exhibits strong Momentum and VGM Style Scores of B, supported by a 1.9% share price increase over the past four weeks. Analyst sentiment is positive, with four analysts raising fiscal 2025 earnings estimates, boosting the Zacks Consensus Estimate by $0.44 to $2.34 per share, and an average earnings surprise of +45.4%, positioning TMDX as a potential short-list candidate for momentum investors.

Analysis

TransMedics Group (TMDX) presents a compelling case for momentum-focused investors, supported by several positive quantitative signals despite its neutral Zacks Rank of #3 (Hold). The company earns a 'B' grade for both its Momentum and composite VGM Style Scores, indicating strong technical and fundamental characteristics. This is reinforced by a 1.9% share price increase over the past four weeks and a significant history of outperformance, demonstrated by an average earnings surprise of +45.4%. Critically, forward-looking sentiment from analysts is improving, with four upward earnings estimate revisions for fiscal 2025 over the last 60 days. These revisions have elevated the Zacks Consensus Estimate for fiscal 2025 by $0.44 to $2.34 per share, suggesting that underlying earnings power may be stronger than the current 'Hold' rating implies.

Key Decisions for Investors

• Investors with a momentum-driven strategy should consider TMDX, given its favorable 'B' Momentum Score and positive analyst earnings revisions for fiscal 2025.
• The stock's #3 (Hold) rating from Zacks warrants some caution, suggesting that investors should weigh the strong momentum signals against potential valuation or other factors that temper a more bullish rating.
• Given the significant +45.4% average earnings surprise, upcoming earnings reports should be monitored closely as continued outperformance could serve as a key catalyst for a potential rating upgrade and further share price appreciation.